Investment accounts for dummies
Clinical cure was defined as a negative follow-up toxin assay and absence of diarrhea on day 6 of therapy. Using this definition, 90 of patients treated with metronidazole and 98 treated with vancomycin were cured of mild CDI, but cure rates were lower in the severe disease group treated with metronidazole (76) compared with vancomycin (97). Although widely cited as evidence that vancomycin is superior to metronidazole for the treatment of severe CDI, this study has potential limitations, including nonstandard dose of metronidazole and using an invalidated definition of cure (a negative follow-up toxin assay) when metronidazole is known to be inferior to vancomycin for microbiological end points during CDI therapy (52).
Most importantly, the definition of mild CDI in the trial included many patients who would be considered as having severe CDI by the proposed definition based on cohort studies in this treatment guideline. Although the intravenous formulation of vancomycin can be compounded by inpatient hospital pharmacies and some outpatient pharmacies at approximately half this cost, the cost difference remains substantial and can impair compliance.